Background: Neuromyelitis optica (NMO) is associated with destructive inflammatory lesions, re-
Optical coherence tomography (OCT) utilizes scanning infrared light to image the retina. 9 The thickness of the retinal nerve fiber layer (RNFL) can be measured accurately via optical interferometry. 10, 11 Using histopathology, a correlation has been demonstrated between optic nerve axonal count and the thickness of the RNFL. 12 Optic atrophy and RNFL thinning are noted features in many patients with MS. [13] [14] [15] Even without a history of optic neuritis (ON), the RNFL by OCT in MS is typically thinner than in normal controls. 16 RNFL correlates with visual function, [17] [18] [19] [20] [21] gray and white matter brain volumes, 22, 23 and overall disability in MS. 24 The use of OCT has been proposed as a potential biomarker of axonal degeneration in MS. 25 The following investigation sought to describe the differences in RNFL thickness between NMO and MS. Our hypothesis is that since NMO is associated with severe relapses, less recovery, more destructive lesions, and more axonal injury than MS, it will have a thinner RNFL in those who have had ON after adjusting for visual outcome.
METHODS This study was approved by the local Human
Research Protection Office/Institutional Review Board, and all subjects provided informed consent. NMO was defined by three of the four following criteria: ON, longitudinally extensive transverse myelitis, positive NMO-IgG, 26 and brain MRI not meeting diagnostic criteria for MS, as modified from criteria of Wingerchuk et al. 27 Any subject who met criteria for an NMO spectrum disorder was included, regardless of whether they had been affected by a clinical episode of ON. Five subjects in the NMO group did not have a clinical episode of ON, but all had a positive NMO-IgG. Four of the five had recurrent myelitis. All subjects with NMO and ON also had spinal cord involvement. An additional inclusion criterion was age 18 -65 years. Exclusion criterion included no other ocular pathology that could affect vision. Out of the available cohort of 26 NMO subjects at this institution, 4 were excluded (one was under age 18, one was over age 65, one was lost to follow-up, and one had diabetic retinopathy). Subjects with MS included those with clinically definite MS by Poser criteria, along with clinically isolated syndrome (CIS) at high risk defined by an abnormal brain MRI. All subjects with MS had at least one prior episode of clinical ON in at least one eye, 6 months or more before inclusion. The 6-month cutoff was based upon a published, prospective study which demonstrated a plateau in the decline of the RNFL at this time. 28 Subjects with MS were preferentially recruited to have had ON with severe onset and poor recovery in order to match the visual acuity (VA) with the NMO cohort.
VA was measured by a Snellen 20-foot wall chart. Contrast sensitivity (CS) was measured by a 5% contrast sensitivity chart 29, 30 in an illuminated cabinet at 3 meters (Precision Vision, IL). Best vision was obtained with prescription glasses and pinhole occluder. OCT measurements of RNFL were obtained by a trained technician on a Zeiss Stratus OCT III with v4.0 software. In those eyes with poor visual function, OCT was obtained by external fixation of the good eye as the technician assessed the quality of the scan.
Statistical analyses utilized linear mixed modeling to account for two eyes within a single individual. Disease duration, age, and number of episodes of ON per eye were controlled within the model. Models were used to compare the difference between eyes in NMO and MS, after a clinical episode of ON, based upon clinical outcomes of 1) visual acuity and 2) contrast sensitivity. Group comparisons used Student t test, Wilcoxon rank sum, or 2 analysis when appropriate. OCT was evaluated as the average overall RNFL, along with the RNFL for each quadrant. In order to create clustered boxplots for both unaffected and affected eyes, visual acuity after ON was categorized based upon the Ranges of Vision Loss by the International Council of Ophthalmology. 31 Due to low numbers in the moderate (n ϭ 4) and severe (n ϭ 8) categories, these were combined with the profound cases to be categorized as severe.
RESULTS
A total of 69 subjects were included in the study, 22 NMO and 47 MS (table). There were no differences between the two cohorts for age, gender, duration since first episode of ON, or overall disease duration. Subjects with NMO had a higher EDSS score, more use of IV glucocorticoids for ON, an increased number of episodes of ON per eye, a slightly worse contrast sensitivity and visual acuity, and a lower mean RNFL.
After a clinical episode of ON, the overall unadjusted mean RNFL for those with NMO was significantly lower than those with MS. Estimated means by a repeated measures mixed model yielded 54.8 Ϯ 3.7 m for NMO and 76.5 Ϯ 2.4 m for MS. Using the eye within an individual with the thinner RNFL, the odds of falling into the NMO group increased by 8% for every 1 m decrease in RNFL thickness.
The model based upon VA, while also adjusting for age, disease duration, and number of episodes, confirmed that NMO is associated with a thinner overall RNFL compared to MS. After a clinical episode of ON, the adjusted mean RNFL for NMO was 56.7 Ϯ 3.1 m, whereas it was 66.6 Ϯ 2.4 m for MS ( figure 1, p ϭ 0.01) . Examining the quadrants individually ( figure 2) showed that the superior (p Ͻ 0.01) and inferior (p ϭ 0.03) quadrants were thinner in NMO. The nasal (p ϭ 0.09) and temporal (p ϭ 0.5) were not different.
The model based upon CS, while also adjusting for age, disease duration, and number of episodes of ON, again confirmed that after ON, NMO is associated with a thinner RNFL compared to MS. The adjusted mean RNFL for NMO was 61.2 Ϯ 3.0 m, and was 70.3 Ϯ 2.2 m for MS ( figure 3, p ϭ 0.02) . Examining the quadrants individually ( figure 4) showed that the superior (p Ͻ 0.01), inferior (p ϭ 0.03), and nasal (p ϭ 0.03) quadrants were thinner in NMO. The temporal (p ϭ 0.9) quadrant was not different. DISCUSSION This study demonstrated that following a remote episode of ON, NMO was associated with a thinner RNFL than MS after adjusting for visual outcome (acuity or CS), compatible with more axon loss with ON in NMO. The study also found that the superior and inferior quadrants were affected to a greater magnitude in NMO than MS, whereas the temporal quadrants were not demonstrably different.
In this study, findings in unaffected eyes in subjects with MS were consistent with published litera- Figure 1 Average retinal nerve fiber layer thickness in multiple sclerosis vs neuromyelitis optica controlled for visual acuity
Interquartile box plots demonstrate that the adjusted retinal nerve fiber layer is thinner in neuromyelitis optica for those eyes previously affected by optic neuritis (p ϭ 0.01). Those categorized as normal had recovered to Ն20/25 from previous optic neuritis.
Figure 2 Retinal nerve fiber layer quadrant thickness in multiple sclerosis vs neuromyelitis optica controlled for visual acuity
Interquartile box plots demonstrate that the adjusted superior (p Ͻ 0.01) and inferior (p ϭ 0.03) retinal nerve fiber layer is thinner in neuromyelitis optica for those eyes previously affected by optic neuritis. MS ϭ multiple sclerosis; NMO ϭ neuromyelitis optica; VA ϭ visual acuity.
ture. The average RNFL thickness in MS has been previously noted to be 92 m in unaffected eyes, a mean of 85 m in eyes affected by a prior clinical episode of ON, and 105 m in healthy controls. 24 In the present study, the lower RNFL in the affected MS eyes is likely due to preferred selection of individuals with poor visual outcomes to match NMO subjects. In this cohort, the mean RNFL thickness for the unaffected NMO eyes was greater than the unaffected MS eyes (p Ͻ 0.05). The reason for this is not clear. This may be due to a relatively small sample of unaffected eyes (14 unaffected NMO vs 29 unaffected MS) with relatively short disease duration (4 years for NMO vs 27 years for MS) in NMO. Some additional hypothetical explanations may include more common occurrence of subclinical optic neuritis in MS than in NMO; axonal attrition in MS, independent of ON; or increased predilection for MS lesions in the optic chiasm or tracts, leading to bilateral RNFL involvement.
The present NMO cohort had a thinner average RNFL than the unadjusted 78 m previously reported. 32 In the latter published study, blind subjects were excluded, thus eliminating subjects likely to have the thinnest RNFLs. The present NMO group included all identified cases within our institution's patient population. We observed that this cohort of subjects with NMO tended to have very thin RNFL, with 39% of NMO eyes compared to 10% of MS eyes having thickness Յ50 m. In either group, having a RNFL thickness Յ50 m conferred 50% odds of having vision Յ20/100. Another study in NMO reported an unadjusted RNFL of 65 m, which included both affected and unaffected eyes. 33 This is similar to the 71 m in the present study, as reported in the table.
Histopathologic studies of NMO have revealed necrotizing lesions with cavitation, involving both Retinal nerve fiber layer quadrant thickness in multiple sclerosis vs neuromyelitis optica controlled for contrast sensitivity
Interquartile box plots demonstrate that the adjusted superior (p Ͻ 0.01), inferior (p ϭ 0.03), and nasal (p ϭ 0.03) retinal nerve fiber layer is thinner in neuromyelitis optica for those eyes previously affected by optic neuritis. MS ϭ multiple sclerosis; NMO ϭ neuromyelitis optica; CS ϭ contrast sensitivity. Interquartile box plots demonstrate that median retinal nerve fiber layer is thinner in neuromyelitis optica for those eyes previously affected by optic neuritis (p ϭ 0.02).
gray and white matter of the spinal cord. There may be a component of ischemia from thickened blood vessel walls. 5 The intense inflammatory response can result in prominent axonal involvement. 7 MS is characterized by demyelination with relative axonal preservation, as originally described by Charcot. 34 Thus, we hypothesized that if thinned RNFL measured by OCT reflects axon loss, the RFNL would be thinner in NMO than in MS. The data herein lend credence to the concept that OCT can be used to identify axon destruction in the optic nerve using RNFL thickness as a surrogate marker for axon loss. 35 Some caveats of this study should be mentioned. First, the clinical outcome used was central vision, chosen due to its functional relevance. The temporal retinal quadrant serves central vision, and was not different between the two conditions. Whether NMO, at a given level of central acuity, is associated with more severe peripheral vision loss compared to MS is unknown. Second, postgeniculate lesion load within the visual system was not assessed. Lesions there might have accounted for some of the visual acuity decrease, particularly in patients with MS, without necessarily causing alterations detected by OCT. 36 Third, our inclusion criteria for the NMO group included five subjects who would be classified as NMO spectrum disorders. The adjusted analyses only included those eyes affected by clinical ON, meaning that these individuals did not contribute to the adjusted analyses.
At each level of visual function there was considerable overlap in OCT measures, limiting the role of OCT to differentiate the two conditions on an individual basis. Thus, OCT alone is unlikely to serve as a diagnostic test. Nonetheless, if an individual has ON with poor recovery, an RNFL thickness less than 50 m, or involvement of the superior and inferior quadrants, the possibility of NMO should be strongly considered. Other forms of optic neuropathy, such as ischemia and glaucoma, were not evaluated in this study, so the specificity of the test remains unknown. The optic disc and retina can have increased RNFL thickness in acute ON, and may take up to 6 months to resolve. Hence, the role for OCT in predicting prognosis based on findings in the acute situation is also unclear.
Measuring RNFL thickness deserves further research effort, particularly in longitudinal studies to assess its prognostic utility, to assess the effect of therapeutics, and in evaluating other imaging modalities. Furthermore, OCT has potential to yield insights into pathogenetic mechanisms.
